Status:
COMPLETED
Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients
Lead Sponsor:
Alexandria University
Conditions:
Renal Transplantation; Complication
Eligibility:
All Genders
Phase:
NA
Brief Summary
To assess the prevalence and risk factors of hypomagnesemia and its association with calcineurin inhibitor use among Egyptian renal transplant recipients.
Detailed Description
Magnesium (Mg) is the fourth cation in the body and the second most prevalent intracellular cation. Intracellular magnesium concentrations range from 5 to 20 mmol/L; 1-5% of it is ionized, the remaind...
Eligibility Criteria
Inclusion
- Duration more than one year after transplantation.
- Serum creatinine less than 2.5 mg/dL.
Exclusion
- Serum creatinine more than 2.5 mg/dL.
- Patients on diuretics.
- Patients on magnesium supplementation.
- Patients with diabetes mellitus.
- Chronic alcoholism.
- Patients on proton pump inhibitors.
Key Trial Info
Start Date :
May 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05352880
Start Date
May 10 2022
End Date
September 10 2022
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Aexandria University
Alexandria, Egypt